Clinical Trial

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 23, 2023 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC). Participants will receive continuous daily PO dosing of lorlatinib 100mg QD.
Trial Details
NCT Number NCT06092086
Lead Sponsor Guangdong Association of Clinical Trials
Conditions ALK Positive Non-small Cell Lung Cancer
Enrollment 126 participants
Start Date 2023-08-18
Primary Completion 2025-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-23